Predictive Modelling in pharmacokinetics : from in-silico simulations to personalized medicine
INTRODUCTION: Pharmacokinetic parameters assessment is a critical aspect of drug discovery and development, yet challenges persist due to limited training data. Despite advancements in machine learning and in-silico predictions, scarcity of data hampers accurate prediction of drug candidates' pharmacokinetic properties.
AREAS COVERED: The study highlights current developments in human pharmacokinetic prediction, talks about attempts to apply synthetic approaches for molecular design, and searches several databases, including Scopus, PubMed, Web of Science, and Google Scholar. The article stresses importance of rigorous analysis of machine learning model performance in assessing progress and explores molecular modeling (MM) techniques, descriptors, and mathematical approaches. Transitioning to clinical drug development, article highlights AI (Artificial Intelligence) based computer models optimizing trial design, patient selection, dosing strategies, and biomarker identification. In-silico models, including molecular interactomes and virtual patients, predict drug performance across diverse profiles, underlining the need to align model results with clinical studies for reliability. Specialized training for human specialists in navigating predictive models is deemed critical. Pharmacogenomics, integral to personalized medicine, utilizes predictive modeling to anticipate patient responses, contributing to more efficient healthcare system. Challenges in realizing potential of predictive modeling, including ethical considerations and data privacy concerns, are acknowledged.
EXPERT OPINION: AI models are crucial in drug development, optimizing trials, patient selection, dosing, and biomarker identification and hold promise for streamlining clinical investigations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Expert opinion on drug metabolism & toxicology - 20(2024), 4 vom: 11. Apr., Seite 181-195 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Paliwal, Ajita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
In-silico modeling |
|---|
| Anmerkungen: |
Date Completed 25.04.2024 Date Revised 26.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17425255.2024.2330666 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369701585 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369701585 | ||
| 003 | DE-627 | ||
| 005 | 20240427232138.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17425255.2024.2330666 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1390.xml |
| 035 | |a (DE-627)NLM369701585 | ||
| 035 | |a (NLM)38480460 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Paliwal, Ajita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predictive Modelling in pharmacokinetics |b from in-silico simulations to personalized medicine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2024 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Pharmacokinetic parameters assessment is a critical aspect of drug discovery and development, yet challenges persist due to limited training data. Despite advancements in machine learning and in-silico predictions, scarcity of data hampers accurate prediction of drug candidates' pharmacokinetic properties | ||
| 520 | |a AREAS COVERED: The study highlights current developments in human pharmacokinetic prediction, talks about attempts to apply synthetic approaches for molecular design, and searches several databases, including Scopus, PubMed, Web of Science, and Google Scholar. The article stresses importance of rigorous analysis of machine learning model performance in assessing progress and explores molecular modeling (MM) techniques, descriptors, and mathematical approaches. Transitioning to clinical drug development, article highlights AI (Artificial Intelligence) based computer models optimizing trial design, patient selection, dosing strategies, and biomarker identification. In-silico models, including molecular interactomes and virtual patients, predict drug performance across diverse profiles, underlining the need to align model results with clinical studies for reliability. Specialized training for human specialists in navigating predictive models is deemed critical. Pharmacogenomics, integral to personalized medicine, utilizes predictive modeling to anticipate patient responses, contributing to more efficient healthcare system. Challenges in realizing potential of predictive modeling, including ethical considerations and data privacy concerns, are acknowledged | ||
| 520 | |a EXPERT OPINION: AI models are crucial in drug development, optimizing trials, patient selection, dosing, and biomarker identification and hold promise for streamlining clinical investigations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a In-silico modeling | |
| 650 | 4 | |a Personalized medicine | |
| 650 | 4 | |a pharmacogenomics | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a validation | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Jain, Smita |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Sachin |e verfasserin |4 aut | |
| 700 | 1 | |a Wal, Pranay |e verfasserin |4 aut | |
| 700 | 1 | |a Khandai, Madhusmruti |e verfasserin |4 aut | |
| 700 | 1 | |a Khandige, Prasanna Shama |e verfasserin |4 aut | |
| 700 | 1 | |a Sadananda, Vandana |e verfasserin |4 aut | |
| 700 | 1 | |a Anwer, Md Khalid |e verfasserin |4 aut | |
| 700 | 1 | |a Gulati, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Behl, Tapan |e verfasserin |4 aut | |
| 700 | 1 | |a Srivastava, Shriyansh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug metabolism & toxicology |d 2005 |g 20(2024), 4 vom: 11. Apr., Seite 181-195 |w (DE-627)NLM164308237 |x 1744-7607 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:4 |g day:11 |g month:04 |g pages:181-195 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17425255.2024.2330666 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 4 |b 11 |c 04 |h 181-195 | ||